Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Paul B. Chapman, Wilson H. Miller et al.|The Lancet|2012Cited by 3k
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trialThomas Powles, Christopher J. Sweeney, Kobe Yuen et al.|Nature Medicine|2022Cited by 241
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsDirk Schadendorf, Caroline Robert, Georgina V. Long et al.|European Journal of Cancer|2017Cited by 171
Chemotherapy-induced peripheral neuropathy — diagnosis, evolution and treatmentDariusz Iżycki, Ewa Nowak‐Markwitz, Adam Niezgoda et al.|Ginekologia Polska|2016Cited by 22